Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.62 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22109188 | 1.00 | MET (0.72) | METCYP2C9PDE3BPDE3APDE10A | |
| SCHEMBL22109324 | 0.91 | MET (0.70) | METCYP2C9PDE3BPDE3APDE10A | |
| SCHEMBL22109339 | 0.90 | MET (0.61) | METCYP2C9PDE3BPDE3APDE10A | |
| SCHEMBL22109156 | 0.90 | MET (0.58) | METCYP2C9PDE3BPDE3APDE10A | |
| SCHEMBL30948868 | 0.89 | MET (0.75) | METCYP2C9PDE3BPDE3APDE10A | |
| SCHEMBL22109390 | 0.89 | MET (0.75) | METCYP2C9PDE3BPDE3APDE10A | |
| SCHEMBL30948869 | 0.88 | MET (0.68) | METCYP2C9PDE3BPDE3APDE10A | |
| SCHEMBL22109310 | 0.88 | MET (0.68) | METCYP2C9PDE3BPDE3APDE10A | |
| SCHEMBL29314630 | 0.87 | MET (0.71) | METCYP2C9PDE3BPDE3APDE10A | |
| SCHEMBL22109320 | 0.86 | MET (0.68) | METCYP2C9PDE3BPDE3APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258365-B2 | Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof | BETA PHARMA, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| EP-3893872-B1 | ORGANOPHOSPHORUS-SUBSTITUTED COMPOUNDS AS C-MET INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA INC (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-113412112-B | Organophosphorus substituted compounds as c-MET inhibitors and therapeutic uses thereof | 贝达医药公司 | 2024-06-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258365-B2 | Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof | MET, ALK, TYRO3 | MET 1/4885CYP2C9 2085/4885PDE3B 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.